This is the authors' abstract. We don't add key points for this paper.
The demonstration of the dramatic effects induced in patients with rheumatoid arthritis with the use of certain products of the adrenal cortex and the pituitary adrenocorticotropic hormone (ACTH) by Hench and his co-workers1has been followed by the demonstration of the therapeutic value of these products in a wide variety of disease conditions. In most instances the therapeutic value ceases with or shortly after the cessation of treatment.2Nevertheless, the implications and potentialities of this and related treatment are fraught with significance. It was only natural that we should investigate the use of these substances (in this instance only pituitary adrenocorticotropic hormone to date) in ophthalmology. The known effect of these products on the acute inflammatory diseases of structures composed of collagenous tissue2and of mesenchymal tissue rendered the eye a suitable organ for experimental treatment because the sclera and cornea contain such a high collagen content
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Dan M. Gordon (1950) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: